A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

182 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-01

Study Completion Date

2018-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional constipation.

Two arms will be assessed:

* Vibrant Capsule administered 5 times per week
* Sham Capsule administered 5 times per week

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration

NCT02829047

Constipation

TERMINATED NA

A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes

NCT03329027

Constipation

COMPLETED NA

Ease of Use, Tolerability, Efficacy and Safety of the Vibrant Capsule Administered in the Home Environment

NCT02895516

Constipation

WITHDRAWN PHASE2

Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation

NCT03879239

Chronic Idiopathic Constipation

COMPLETED NA

Vibrant Capsule vs. Placebo for Patient Suffering From Constipation

NCT05036369

Constipation Chronic Idiopathic

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional constipation.

Two arms will be assessed:

* Vibrant Capsule administered 5 times per week
* Sham Capsule administered 5 times per week

Subjects will follow a 2 weeks baseline period and then take the Vibrant Capsule for a treatment period of 8 weeks.

Data reporting will be done on an electronic Case Report Form (eCRF) and an eDiary.

Subjects will be asked to refrain from taking any medication or supplement to relieve their constipation, during the entire study period.

After the 14 days of run-in period, the subjects will return and eligibility will be re-assessed. Subjects will be trained on how to use the base unit and will swallow the first capsule on site the day of baseline visit. They will activate and ingest the rest of the capsules at home by themselves, using the base unit.

Subjects will be instructed to complete a simple subject eDiary each day throughout the duration of the study. A final visit will take place at the end of the 8 week treatment period.

Subjects will receive phone calls at least once a week and subject compliance will be monitored during the 8 weeks of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vibrant capsule

Patients will receive the Vibrant capsule 5 times a week for 8 weeks of treatment

Group Type ACTIVE_COMPARATOR

Vibrant capsule

Intervention Type DEVICE

One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.

Sham capsule

Patients will receive the sham capsule (activated, non-vibrating) 5 times a week for 8 weeks of treatment

Group Type SHAM_COMPARATOR

Sham capsule

Intervention Type DEVICE

One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vibrant capsule

One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.

Intervention Type DEVICE

Sham capsule

One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects aged 22 years and older
2. Subjects with Chronic Idiopathic Constipation (CIC) according to Rome III criteria and who have not experienced relief of their symptoms from available therapies
3. Subjects with an average of \<3 Spontaneous Bowel Movements (SBM) per week and ≥1 SBM per week
4. Normal colonoscopy performed within 10 years prior to study participation, unless the subjects are \<50 years old and without alarm signs and/or symptoms
5. Subject signed the Informed Consent Form (ICF)
6. Female subjects must have a negative pregnancy test

Exclusion Criteria

1. History of complicated/obstructive diverticular disease
2. History of intestinal or colonic obstruction, or suspected intestinal obstruction.
3. History of significant gastrointestinal disorder, including any form of inflammatory bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has been treated and is in remission)
4. History of gastroparesis
5. Use of any of the following medications:

* Medications that may affect intestinal motility, prokinetics, anti-depressants, anti-Parkinsonian medications, opiates, opioids, calcium-channel blockers, aluminum/magnesium hydroxide
* With the exception of antidepressants, thyroid or hormonal replacement therapy, when the subject has been on a stable dose for at least 3 months prior to enrollment.
6. Clinical evidence of significant respiratory, cardiovascular, renal, hepatic, biliary, endocrine, psychiatric or neurologic disease.
7. Presence of cardiac pacemaker or gastric electrical stimulator.
8. History of, or current eating disorders, such as anorexia, bulimia, or compulsory overeating.
9. Diagnosis of mega-rectum or colon, congenital anorectal malformation, clinically significant rectocele, history of intestinal resection (with an exception for appendectomy, cholecystectomy and inguinal hernia repair), history of bariatric surgery or evidence of any structural abnormality of the gastrointestinal tract that might affect transit
10. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture or achalasia
11. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)
12. Subjects with pelvic floor dysfunction/defecatory disorder
13. Participation in another clinical study within one month prior to screening.
14. Women who are pregnant or lactating

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No